Efficacy of Shenqi Pollen Capsules for High-Altitude Deacclimatization Syndrome via Suppression of the Reoxygenation Injury and Inflammatory Response
Table 5
Analysis of secondary outcomes.
Secondary outcome
Baseline
Week 7
Week 14
value‡
value§
value||
Placebo group
SPC group
Placebo group
SPC group
Placebo group
SPC group
Myocardial enzymes
CK (IU/L)
122.14 (2.94, 116.42- 128.06)
124.14 (3.34, 117.52- 130.75)
116.53 (2.12, 112.33 - 120.73)
92.30 (1.92, 88.51- 96.10)
104.90 (2.64, 99.67 - 110.13)
99.60 (2.25, 95.13 - 104.08)
<0.001
<0.001
<0.001
CK-MB (IU/L)
21.70 (0.61, 20.49- 22.91)
21.37 (0.49, 20.38-22.35)
19.42 (0.24, 18.95- 19.90)
15.47 (0.23, 14.99- 15.95)
17.48 (0.32, 16.84 - 18.13)
15.89 (0.16, 15.56 - 16.21)
<0.001
<0.001
<0.001
LDH (IU/L)
198.89 (2.29, 194.37- 203.41)
195.87 (2.80, 189.43- 199.48)
170.53 (3.15, 169.37 - 183.31)
156.95 (2.70, 143.89 - 155.19)
151.03 (2.65, 145.78 - 156.27)
133.47 (2.01, 129.49 - 137.46)
<0.001
<0.001
<0.001
Heart function
HR (beats/min)
75.07 (0.45, 74.17- 75.96)
74.36 (0.95, 72.47- 76.25)
71.14 (0.45, 70.24 - 72.03)
70.89 (0.67, 69.56 - 72.22)
70.03 (0.67, 68.69 - 71.37)
70.56 (0.49, 69.56 - 71.50)
<0.001
0.84
0.59
LVEF (%)
64.22 (0.46, 63.30- 65.14)
64.07 (0.40, 63.27- 64.87)
63.51 (0.39, 62.72 - 64.30)
63.45 (0.47, 62.62 - 64.38)
58.87 (0.35, 58.16 - 59.58)
57.90 (0.34, 57.22 to 58.58)
<0.001
0.26
0.405
LVFS (%)
34.12 (0.38, 33.36- 34.88)
34.63 (0.30, 34.03- 35.24)
34.82 (0.27, 34.27 - 35.37)
34.87 (0.31, 34.26 - 35.49)
31.45 (0.29, 30.88 - 32.03)
30.92 (0.22, 30.48 to 31.36)
<0.001
0.94
0.18
Pulmonary artery inner diameter (mm)
27.34 (0.12, 24.38- 30.30)
26.84 (0.09, 24.62- 29.05)
24.14 (0.07, 24.00 - 24.28)
24.27 (0.05, 24.16 - 24.37)
20.83 (0.12, 20.58 - 21.08)
20.93 (0.05, 20.83 to 21.03)
<0.001
0.11
0.367
PAOV (m/s)
81.78 (0.54, 80.7- 82.86)
80.67 (0.47, 79.73- 81.60)
95.14 (0.52, 94.11 - 96.17)
93.26 (0.54, 92.19 - 94.34)
81.78 (0.54, 80.70 - 82.86)
81.01 (0.51, 79.99 to 82.02)
<0.001
0.01
0.60
PASP (mmHg)
2.79 (0.31, 2.7- 2.85)
2.73 (0.30, 2.67- 2.79)
3.64 (0.07, 3.51 - 3.77)
3.45 (0.35, 3.38 - 3.52)
2.73 (0.03, 2.67 - 2.79)
2.71 (0.03, 2.64 to 2.78)
<0.001
0.18
0.01
The data are presented as the means (SE, 95% CI). RBC = red blood cells, Hb = hemoglobin, Hct = hematocrit, MCV = mean corpuscular volume. CK = creatine kinase, CK-MB = creatine kinase-MB, LDH = lactate dehydrogenase. HR = heart rate, LVEF = left ventricular ejection fraction, LVFS = left ventricular fractional shortening, PAOV = pulmonary artery opening velocity, PASP = pulmonary artery systolic pressure. Comparisons of the mean differences were made at weeks 7 and 14 from the final adjusted linear mixed model, .‡The overall change over time, .§The average group difference, .||The interaction between time and group, .
